+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 20Years +
MALE
ID06461793

Safety Study of Increased Radiation Dose Using SpaceOAR Hydrogel and Hormone Therapy in Men Over 20 with High-Risk Localized Prostate Cancer

Led by Samsung Medical Center · Updated on 2024-06-21

33

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research focuses on patients with high-risk localized prostate cancer who are undergoing low-fractionation curative radiation therapy combined with hormone therapy. It aims to assess the safety of increasing radiation dose after injecting a biodegradable material called SpaceOAR, which helps protect the rectum during treatment. The study is a phase II trial designed to evaluate side effects and safety outcomes in this patient group. Participants receive an injection of the biodegradable hydrogel SpaceOAR between the prostate and rectum to reduce radiation exposure to normal tissues. Following the injection, patients undergo hypofractionated radiation therapy, delivering a higher biological effective dose than conventional methods, combined with hormone therapy. The study specifically monitors side effects related to the radiation dose escalation and the biodegradable material injection. During the study, patients are closely monitored for rectal bleeding and other radiation-related side effects for up to three years after radiation therapy. Additional assessments include biochemical recurrence-free survival, progression-free survival, overall survival, and quality of life measured with the EPIC questionnaire over five years. Side effects related to the biodegradable material are tracked for up to five years, with acute adverse events checked 3-6 months post-treatment. The study offers long-term follow-up to evaluate safety and patient outcomes comprehensively.

CONDITIONS

Brief Title

Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)

Research Team

W

Won Park, M.D., Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here